• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Candel Therapeutics Inc.

    3/13/25 4:45:53 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CADL alert in real time by email
    S-8 1 d932796ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 13, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    CANDEL THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   52-2214851

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    117 Kendrick St., Suite 450

    Needham, MA

      02494
    (Address of Principal Executive Offices)   (Zip Code)

    Candel Therapeutics, Inc. 2021 Stock Option and Incentive Plan

    Candel Therapeutics, Inc. 2021 Employee Stock Purchase Plan

    (Full title of the plans)

    Paul Peter Tak, M.D., Ph.D.

    President and Chief Executive Officer

    Candel Therapeutics, Inc.

    117 Kendrick St, Suite 450

    Needham, MA 02494

    (Name and address of agent for service)

    (617) 916-5445

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    William D. Collins, Esq.

    Finnbarr D. Murphy, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This registration statement on Form S-8 relating to the 2021 Stock Option and Incentive Plan (the “2021 Plan”) and the 2021 Employee Stock Purchase Plan (“the “2021 ESPP”) (together, the “Plans”) of Candel Therapeutics, Inc. is being filed for the purpose of registering additional securities of the same class as other securities for which a registration statement on Form S-8 relating to the Plans has previously been filed and is effective. Accordingly, pursuant to General Instruction E, the information contained in the registrant’s registration statements on Form S-8 (File Nos. 333-258279, 333-263961, 333-270967 and 333-278294) is hereby incorporated by reference and made a part of this registration statement, except as presented below in Part II, Item 8. Exhibits.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.

    Exhibits.

    EXHIBIT INDEX

     

    Exhibit

    No.

       Description
    4.1    Amended and Restated Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 30, 2021).
    4.2    Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 30, 2021).
    4.3    Amendment to the Amended and Restated Bylaws of Candel Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 30, 2024).
    4.4    Second Amended and Restated Investors’ Rights Agreement (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-257444)).
    5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of KPMG LLP, Independent Registered Public Accounting Firm.
    23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    2021 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-257444)).
    99.2    2021 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1, as amended (File No. 333-257444)).
    107*    Filing Fee Table.

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Needham, State of Massachusetts, on this 13th day of March, 2025.

     

    CANDEL THERAPEUTICS, INC.
    By:  

    /s/ Paul Peter Tak

     

    Name: Paul Peter Tak, M.D., Ph.D.

    Title: President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Paul Peter Tak, M.D., Ph.D. and Charles Schoch, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.


    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

    Name    Title    Date

    /s/ Paul Peter Tak

       President, Chief Executive Officer and Director    March 13, 2025
    Paul Peter Tak, M.D., Ph.D.    Principal Executive Officer   

    /s/ Charles Schoch

       Interim Chief Financial Officer    March 13, 2025
    Charles Schoch    Principal Financial Officer and Principal Accounting Officer   

    /s/ Paul B. Manning

       Director    March 13, 2025
    Paul B. Manning

    /s/ Edward J. Benz, Jr.

       Director    March 13, 2025
    Edward J. Benz, Jr., M.D.

    /s/ Renee Gaeta

       Director    March 13, 2025
    Renee Gaeta

    /s/ Nicoletta Loggia

       Director    March 13, 2025
    Nicoletta Loggia

    /s/ Christopher Martell

       Director    March 13, 2025
    Christopher Martell

    /s/ Gary J. Nabel

       Director    March 13, 2025
    Gary J. Nabel, M.D., Ph.D.

    /s/ Diem Nguyen

       Director    March 13, 2025
    Diem Nguyen, Ph.D., M.B.A.

    /s/ Joseph C. Papa

       Director    March 13, 2025
    Joseph C. Papa
    Get the next $CADL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CADL

    DatePrice TargetRatingAnalyst
    10/28/2025$15.00Overweight
    Stephens
    9/3/2025$7.00Buy → Neutral
    BofA Securities
    6/30/2025$23.00Buy
    H.C. Wainwright
    2/20/2025$25.00Buy
    Citigroup
    2/19/2025$20.00Buy
    Canaccord Genuity
    2/7/2025$15.00Buy
    BofA Securities
    12/2/2022$11.00Buy
    H.C. Wainwright
    11/19/2021$18.00Outperform
    BMO Capital
    More analyst ratings

    $CADL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Candel Therapeutics with a new price target

    Stephens initiated coverage of Candel Therapeutics with a rating of Overweight and set a new price target of $15.00

    10/28/25 8:02:46 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Candel Therapeutics from Buy to Neutral and set a new price target of $7.00

    9/3/25 8:04:26 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Candel Therapeutics with a new price target

    H.C. Wainwright resumed coverage of Candel Therapeutics with a rating of Buy and set a new price target of $23.00

    6/30/25 7:59:11 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CADL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Tyagarajan Seshu

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:04:50 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Nichols William Garrett

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:03:33 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Financial Officer Schoch Charles

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    1/28/26 5:02:42 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CADL
    SEC Filings

    View All

    Candel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

    12/5/25 8:30:52 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Candel Therapeutics Inc.

    10-Q - Candel Therapeutics, Inc. (0001841387) (Filer)

    11/13/25 8:30:54 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Candel Therapeutics, Inc. (0001841387) (Filer)

    11/13/25 8:15:27 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CADL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company's common stock, with a per share exercise price of $5.84. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on

    2/2/26 4:05:00 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

    NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced it will host a virtual Research and Development (R&D) Event from 11:00 am – 1:45 pm ET on Friday, December 5, 2025. Candel's R&D Day will include presentations and panel discussions from its executive leadership, clinical investigators, scientific advisors, and key collaborators. The event will provide an extensive overview of the Company's viral immunotherapy approach and oncology-focused pipeline. Click here to register for th

    11/17/25 4:05:00 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized                                                        Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026Announced encouraging updated survival data for patients enrolled in its phase 1b clinical trial of CAN-3110 (li

    11/13/25 8:25:00 AM ET
    $CADL
    $TRIN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    $CADL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $7,500,000 worth of shares (1,250,000 units at $6.00) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    12/18/24 4:11:47 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CADL
    Leadership Updates

    Live Leadership Updates

    View All

    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

    NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Bali Pulendran, Ph.D. to Candel's Research Advisory Board (RAB). Dr. Pulendran, an internationally recognized expert in systems immunology and vaccinology, who has pioneered the use of systems approaches to understand human immune responses, will bring his deep expertise to the RAB, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-311

    10/16/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

    NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Carl H. June, M.D., to Candel's Research Advisory Board (RAB). Dr. June, an internationally recognized expert in cancer immunotherapy, and a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy, will bring Candel his deep expertise, as Candel continues to advance its lead viral immunotherapy candidate CAN-2409 across multiple solid tumor indications and CAN-3110 f

    9/2/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

    NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately. "Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO," said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. "He has effectively

    6/23/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CADL
    Financials

    Live finance-specific insights

    View All

    Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

    NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Candel management will host a webcast and conference call on Tuesday, June 3, 2025, at 1:00PM ET. The call will discuss the Company's positive phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer, which demonstrated a statistically significant 30% reduction in disease recurrence compared with placebo when combined with standard-of-care radiation therapy. The discussion will follow Dr.

    5/27/25 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

    Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined with radiation therapy for intermediate-to-high risk, localized prostate cancerThe safety profile of CAN-2409 was generally consistent with previous studies, with no new safety signals identifiedThe phase 3 clinical trial was conducted under a Special Protocol Assessment (SPA) with the FDA NEEDHAM, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients

    12/11/24 7:00:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

    Expects to announce clinical trial data from multiple oncology programs in the second half of 2023Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. "Our 2022 achievements reaffirm our belief that using our viral immunotherapies to mobilize the patient's immune system to fight cancer represents a promising a

    3/30/23 8:00:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CADL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Candel Therapeutics Inc. (Amendment)

    SC 13G/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    2/9/23 9:59:40 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    2/14/22 4:40:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care